CanSinoBIO is a biopharmaceutical company dedicated to providing global solutions for the prevention and treatment of infectious diseases through research & development, manufacturing and commercialization of vaccine products for human use.

康希诺生物

Tianjin CanSino Biotechnology Inc. | 624 followers on LinkedIn. Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

CanSino has established bacterial and cell/viral culture pilot facilities in compliance to the current GMP standard.

Co-founder, Chairman and CEO at CanSino Biologics Inc.

Xuefeng Yu

VP, CanSino

Tao Zhu

Technician at CanSino Biotechnology Inc

Wanyu Zhu

Senior Admin Officer at CanSinoBIO technology Inc.

Sheila Wang

Tianjin CanSino Biotechnology Inc.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CanSino Biologics Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 16, 2024 8:36 PM	bc043cb2
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 16, 2024 8:36 PM	b9df5a55
crunchbase trigger	general	Nov 16, 2024 8:36 PM	64fd3a03
crunchbase profile	general	Nov 16, 2024 8:44 PM	e938ee28
li profile	general	Nov 16, 2024 8:36 PM	d057dca0
translate crunchbase fundingrounds	general
peers	general	Nov 16, 2024 8:36 PM	184956d9
news basic	general	Nov 16, 2024 8:36 PM	68cc5aab
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

6185

COM:CANSINOTECH

康希诺生物

Last Close

29.15

22/11 08:08

Market Cap

6.49B

Beta: -

Volume Today

1.73M

Avg: -